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Abstract
One fundamental, but understudied mechanism of gene regulation in disease is allele specific 
expression (ASE), the preferential expression of one allele. We leveraged RNA-seq from human 
brain to assess ASE in autism spectrum disorder (ASD). When ASE is observed in ASD, the allele 
with lower population frequency (minor allele) is preferentially more highly expressed than the 
major allele, opposite than the canonical pattern. Importantly, genes showing monoallelic 
expression (MAE) in ASD are enriched in those down-regulated in ASD postmortem brain and in 
genes harboring de novo mutations in ASD. Two regions, 14q32 and 15q11, containing all known 
orphan C/D box snoRNAs, are particularly enriched in shifts to higher minor allele expression. We 
demonstrate that this allele shifting enhances snoRNA targeted splicing changes in ASD-related 
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target genes in idiopathic ASD and 15q11-q13 duplication syndrome. Together, these results 
implicate allelic imbalance and dysregulation of orphan C/D box snoRNAs in ASD pathogenesis.
Autism spectrum disorder (ASD) is defined by deficits in social interaction and repetitive 
behaviors1,2 and has a global prevalence of approximately 1 case per 68 people1. Although 
genetic factors contribute to a substantial proportion of disease liability the genetics of ASD 
are complex with contributions from both rare and common alleles, including de novo 
mutations and polygenic inheritance2. Despite this heterogeneity and polygenicity, we have 
previously identified a reproducible shared pattern of gene expression alterations in human 
postmortem cortex from subjects with idiopathic ASD3 and replicated this signal in 
independent subjects with idiopathic ASD and dup15q4. This gene expression signal may be 
mediated by epigenetic factors5,6, such as DNA methylation7 or histone modification6, in 
addition to underlying genetic variation.
Allele specific expression (ASE) is a form of genetic regulation in which expression of 
mRNA at a specific locus is biased towards a specific allele8–10. An extreme case of ASE is 
genomic imprinting, whereby a particular allele is completely silenced8,11. But, most ASE 
represents more subtle shifts in the allelic ratio rather than complete silencing of one 
allele9,12 as evidenced by the observations of preferential reduced expression of mutant 
disease alleles, and a substantial proportion of cis-acting expression quantitative trait loci 
(cis-eQTL) are mediated by ASE12–14. Indeed, cis-eQTL and ASE are complementary 
mechanisms involved in the regulation of gene expression15. One advantage of analyzing 
ASE in patient tissues is that it is less influenced by genetic, environmental, and technical 
confounders because ASE relies primarily on within-subject expression comparisons, rather 
than comparisons between subjects15,16.
A number of diseases can be attributed to abnormalities in ASE17,18. For example, Prader-
Willi syndrome (PWS) and Angelman syndrome (AS) are rare neurodevelopmental 
disorders resulting from deletions within the highly-imprinted region, 15q11-q13. 
Conversely, recurrent maternally-derived duplications of this region lead to dup15q, a rare, 
but penetrant syndromic form of ASD comprising approximately 1% of cases19. Although 
duplications generally increase gene expression19, varied patterns are observed across genes 
in the region impacted by dup15q due to complex local regulatory mechanisms4,19–21.
In addition to known imprinted regions, ASE extends to over 5% of autosomal genes and is 
especially enriched in transmembrane receptors and cell surface molecules9. When not 
associated with parent-of-origin imprinting, such monoallelic expression (MAE) is random 
MAE (RMAE), which may be important for cell-type specific gene dosage effects10,22. 
Moreover, emerging evidence suggests that RMAE is involved in neurodevelopmental 
disorders, as recently observed for developmental dyspraxia caused by RMAE in FOXP223. 
In this case, ASE may contribute to disease susceptibility by exacerbating the deleterious 
effects of a mutation via haploinsufficiency, or mosaic somatic expression.
Except for one notable study, which showed that ASE in several specific genes may play a 
role in a subset of ASD cases8, the role of genome-wide ASE has not been explored in a 
sufficiently powered cohort. The overall paucity of ASE studies in brain disorders, such as 
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ASD, is likely due to several challenges including limited access to human brain tissue, 
small sample sizes, incomplete transcriptome-wide genotyping data, and reference bias in 
mapping transcripts8,12,13,24,25. Reference bias is attributable to reduced mapping of 
alternative-allele-containing RNA-seq reads (due to a greater number of mismatches) and 
can generate up to 40% false positive signals if not properly addressed9,13,25. However, 
when these issues are properly addressed, ASE can be a highly robust approach to 
investigate the relationship between epigenetic variation and gene expression underlying 
diseases15. Here, we applied an optimized ASE pipeline in a relatively large sample of 
postmortem brains from idiopathic ASD and control subjects. We found that most loci 
showing ASE are shared between ASD and control, which is contrast to ASE between the 
two brain regions, cerebral cortex and cerebellum, which shows large differences24. A small 
proportion of loci do manifest significant reproducible ASE changes between ASD and 
controls, which may represent a novel form of genetic regulation related to disease 
pathogenesis.
Results
ASE identification in brain
We first developed an optimized ASE identification pipeline (Fig. 1; Methods) to overcome 
potential challenges, such as reference bias in mapping transcripts, lack of transcriptome-
wide genotyping data, and allelic expression bias introduced by ethnicity. We collected 263 
postmortem brain tissue samples from frontal cortex (Brodmann area (BA)9), temporal 
cortex (BA41-42-22 (BA41)), and cerebellar vermis from 96 individuals (40 controls and 56 
ASD cases including 8 cases with dup15q). Gene expression profiling was performed using 
RNA-seq4, and genotyping was conducted on arrays (Methods).
To overcome reference bias, we generated a novel reference genome masked for single 
nucleotide polymorphisms (SNPs) that could contribute to mapping bias. We compiled ~40 
million possible variants based on the union of SNPs called from RNA-seq data 
(Supplementary Fig. 1a) and SNPs already identified from microarray probe sets and the 
1000 Genomes26,27 (Methods). We prepared a custom human reference genome after 
masking these SNPs (Methods). Using this masked reference, we identified and removed 
11.13% of SNPs that showed biased mapping from a simulated dataset18 (Methods). To 
collect transcriptome wide genotyping data from our brain samples, we performed 
imputation from genotyping array and RNA-seq based genotyping (Methods; 
Supplementary Fig. 1b and 1c), and ancestry was identified for all samples (Methods; 
Supplementary Fig. 1d).
For investigation of group-level ASE patterns across cases and brain regions, 1,163,249 
heterozygous SNPs in 21,929 genes were used following quality control (Methods), and 
their significance was quantified using a linear mixed model to account for sample variation 
and covariates (Supplementary Table 1; Methods). The values of excluded covariates 
showed balanced distributions between control and ASD (Supplementary Fig. 1e; Methods).
We filtered out all SNPs showing ancestry-associated variation to avoid any potential effects 
of population stratification (Methods). ASE was also assessed within each individual sample 
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for quality-controlled SNPs using Fisher’s exact test (Methods). Both individual and group-
level ASE studies underwent multiple testing correction for independent SNPs after linkage 
disequilibrium (LD)-based SNP pruning (Methods). Among the alleles showing ASE, we 
also filtered out reference biased SNPs related to proximal indels (Methods). As expected, 
SNPs within the same haplotype blocks show similar allelic expression patterns 
(Supplementary Fig. 1f and 1g).
Common ASE patterns in brain tissues
For external validation, we performed two analyses. First, we compared genes with evidence 
of ASE with those in dbMAE, an integrated database compiled from ASE analyses across 
human and mouse tissues22. Although this database contains data from mostly non-neural 
tissues, genes manifesting ASE in our study showed significant overlap with those in 
dbMAE (Supplementary Fig. 2a). Furthermore, although assessed separately in each brain 
region, there was strong concordance in common ASE genes between regions in our data 
(Fig. 2a and Supplementary Table 2). For example, the overlap between genes showing ASE 
in the two cortical regions, BA9 and BA41 is extremely high (odds ratio (OR)=221.00 and p-
value<2.2e-16; Supplementary Fig. 2b), whereas the degree of overlap between two more 
developmentally and evolutionarily distinct brain regions, cortex and cerebellum, is 
substantial, but lower than in the two more similar cortical regions (between BA9 and 
vermis: OR=49.00 and p-value<2.2e-16; between BA41 and vermis: OR=72.54 and p-
value<2.2e-16). This is consistent with recent GTEx data analysis showing that the 
cerebellum has a distinct ASE pattern relative to other brain tissues24.
For further external validation, we applied the specific methods and pipeline used in the 
primary analysis of GTEx24 (Supplementary Fig. 2c). Both the GTEx pipeline and our 
modified approach showed similar patterns of distinct ASE between the cortex and 
cerebellum. In the GTEx data, the mean of ASE rates from the two cerebral cortical regions 
and cerebellum show significant correlation with our data (R2=0.9995 and p-value=0.0098; 
Methods).
The distribution of expression of imbalanced alleles was significantly shifted lower than 
balanced alleles (Kolmogorov-Smirnov (KS) test, p-value<2.0e-16, the means of 
log2(RPSM): 0.37 vs 0.71; Supplementary Fig. 2d). ASE was also enriched at known 
imprinted genes including the targets of RNA binding proteins, FMRP28, ELAVL1 (HuR)29, 
and RBFOX130 (Fig. 2b; Methods). Genes showing evidence for ASE were also 
preferentially enriched for neuronal31 and astrocyte markers31 (Fig. 2b and Supplementary 
Fig. 2e). Consistent with a strong neuronal signal, they were also enriched for genes 
encoding proteins of the postsynaptic density (PSD)32, similar to previous observations9. 
Remarkably, across all three brain regions, ASE genes are enriched for genes previously 
shown to be down-regulated in postmortem brain from patients with ASD4 (Supplementary 
Fig. 2f). In cerebral cortex, genes down-regulated in ASD postmortem brain were enriched 
among those showing ASE. Those up-regulated in ASD were depleted in those showing 
ASE; 37% of down-regulated genes were subject to ASE. In cortex, genes up-and down-
regulated in ASD were 448 and 503, respectively. However, among ASE genes, 84 and 181 
genes were respectively up-and down-regulated in ASD (OR=1.92 and p-value=7.03e-06). 
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Both ASE genes and those down-regulated in ASD are involved in synaptic transmission and 
vesicular transport4, consistent with their enrichment in PSD and targets of FMRP28, HuR29, 
and RBFOX1 genes previously implicated in ASD4. Importantly, genes showing ASE also 
showed significant enrichment in genes harboring de novo ASD risk variants identified in 
two different studies32,33 (Fig. 2c; Methods). However, genes manifesting ASE did not show 
any significant enrichment with GWAS data from several major psychiatric diseases 
including attention-deficit/hyperactivity disorder (ADHD)34, bipolar disorder (BPD)34, 
major depression disorder (MDD)34, schizophrenia (SCZ)34, and ASD34,35.
ASE patterns shared across idiopathic ASD cases and controls
Similar to controls, idiopathic ASD cases showed tissue specific ASE across the three brain 
regions (Fig. 3a, Supplementary Fig. 3a, and Supplementary Fig. 3b). Since the two cortical 
regions showed strong overlap in ASE and cortical manifestations of transcriptional 
dysregulation in ASD are more prominent than those in cerebellum4, we focused on the 
cerebral cortex for most of the subsequent case-control comparisons. We found that SNPs 
showing ASE are broadly and evenly distributed throughout the genome in both control and 
idiopathic ASD (Fig. 3b). The majority of genes exhibiting ASE (70.41%) are shared across 
the case and control groups providing further confidence in the reproducibility of these 
results (Fig. 3c and Supplementary Table 3). Nevertheless, fewer genes showing ASE are 
observed in idiopathic ASD compared to controls (Fig. 3c), and this was recapitulated when 
studying the rate of ASE at the level of each individual sample (Fig. 3d).
Comparing biological pathway enrichment in cases and controls revealed overlap and 
differences in ASE gene function. Genes exhibiting ASE in both idiopathic ASD and control 
are enriched in phosphoprotein, RNA splicing, and neuron projection pathways (Fig. 3e and 
Supplementary Table 4). Genes exhibiting control-specific ASE are significantly enriched 
for pathways related to growth cone and synapse (Supplementary Fig. 3c and Supplementary 
Table 4). Though there are fewer idiopathic ASD-specific ASE genes than control-specific 
ASE genes, those showing idiopathic ASD-specific ASD are significantly enriched for 
pathways involved in transport (Supplementary Fig. 3d and Supplementary Table 4). Genes 
exhibiting ASE in both idiopathic ASD and controls show significant enrichment in genes 
harboring de novo ASD risk variants (Supplementary Fig. 3e; OR=1.68, p-value=5e-04 for 
ASD1; OR=3.83, p-value=0.001 for ASD2). However, control-specific and idiopathic ASD-
specific ASE genes do not show any enrichment with either the rare de novo ASD risk 
variants or common variants from GWAS data (Supplementary Fig. 3e).
Quantitative allelic imbalance in idiopathic ASD
ASE is not always completely monoallelic and may involve subtle shifts in allelic balance, 
whereby one allele is quantitatively favored over the other8,15. To investigate this full 
spectrum of ASE in control and idiopathic ASD, we compared the distributions of the minor 
allele expression fraction for SNPs in which these calls are high quality (Methods; Fig. 4a). 
As expected, the majority of heterozygous alleles show no evidence of ASE (herein called 
“balanced”) with the fraction near 50%. A much smaller number of alleles show complete 
MAE and accordingly their fractions are either 0% or 100%. Finally, we define 
“imbalanced” alleles as those that lie between the balanced and MAE distribution ranges. 
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Controls had a higher density of balanced alleles than ASD cases while idiopathic ASD 
cases showed more imbalanced alleles (Supplementary Fig. 4a and Fig. 4a). However, 
controls showed significantly more major allele MAE for low frequency alleles (minor allele 
frequency (MAF)<0.05) compared to idiopathic ASD (Supplementary Fig. 4b). These 
patterns were recapitulated in the pseudoautosomal region (PAR) of the chromosome X 
(Supplementary Fig. 4c).
We next investigated whether the differential ASE pattern was related to the MAF genome-
wide (Fig. 4b and Supplementary Fig. 4b). The disease specific patterns (balanced alleles: 
control > idiopathic ASD; imbalanced alleles: control < idiopathic ASD) were largely stable 
across the range of MAFs. However, we observed that complete MAE was strictly limited to 
rare alleles. Furthermore, preferential major allele expression becomes stronger as the minor 
allele frequency decreases (Fig. 4c). Major alleles exhibiting MAE are enriched in genes that 
are more tolerant of loss of function12 (LoF; Methods) and missense mutations compared to 
those showing balanced expression (chi-square test p-value=0.0134; Fig. 4d). This suggests 
that a bias towards the major allele expression may provide a buffer against the 
consequences of potentially deleterious mutations. Remarkably, this preferential pattern of 
major allele expression shows a significant interaction with idiopathic ASD (Fig. 4e). On 
average, minor alleles are preferentially more highly expressed in idiopathic ASD than in 
controls (Minor/major allele ratio: 0.79 in ASD and 0.75 in control; chi-square test p-
value=7.33e-11). Together, these results indicate that rare and potentially pathogenic alleles 
are more likely to be unmasked in idiopathic ASD brain by the patterns of ASE.
Monoallelic expression occurs primarily from the major allele
Overall, we observed a strong bias towards expression of the major allele for sites in genes 
harboring rare minor alleles and MAE alleles. However, unlike global ASE patterns (Fig. 3c) 
MAE patterns differed between cases and controls (Fig. 5a). Although MAE SNPs were 
observed across the genome (Supplementary Fig. 5), there was an approximately 2-fold 
enrichment on chromosome 15 harboring a number of known imprinted loci (Supplementary 
Table 5). Reasoning that this could provide a convergent mechanism underlying the co-
occurrence of dup15q syndrome and idiopathic ASD, we next investigated MAE in 8 cases 
of dup15q. We observed a substantial enrichment of minor allele MAE in ASD and dup15q 
compared to controls (Fig. 5b; 2.5 and 2.7fold, respectively). This genome-wide enrichment 
pattern persisted when SNPs were analyzed at individual genes (Supplementary Fig. 6a and 
6b).
Overall, minor allele predominant MAE was significantly enriched on chromosomes 14 and 
15 (Fig. 5c) with ASD and dup15q showing stronger patterns compared to controls. 
Compared to chromosome 14, chromosome 15 exhibited a substantially higher minor allele 
MAE fraction in both ASD and dup15q than controls (3.9- and 1.6-fold, respectively; chi-
square test p-values<2.2e-16 and 0.0184, respectively; Fig. 5c and Supplementary Table 5). 
Chromosomes 3, 6, and 7 also showed higher fractions of minor allele MAE in ASD and 
dup15q subjects than controls, of which only chromosome 3 was significant in both (4.2- 
and 9.8-fold, respectively; chi-square p-values=0.0022 and 8.89e-08, respectively). 
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However, we focused on the chromosome 14 and 15 for further analysis since chromosome 
3 had an overall lower degree of minor allele MAE.
Pathway analysis of minor allele MAE genes showed strong enrichment for known 
imprinted genes, as expected (Fig. 5d). Interestingly, these MAE genes were enriched for 
distinct pathways from typical ASE genes that favor major allele expression (Fig. 2b) 
suggesting that orthogonal biological processes are involved. For example, genes showing 
minor allele MAE showed no overlap with astrocyte markers31, PSD32, or ASD-specific 
down-regulated genes4 (Supplementary Fig. 6c). However, they did show enrichment for 
genes harboring known rare mutations increasing risk for ASD (SFARI genes36; Methods) 
whereas other classes of genes showing ASE did not. Like genes that manifest ASE (Fig. 
2c), major allele MAE genes show significant enrichment with genes associated with the 
rare de novo ASD risk variants (Supplementary Fig. 6d). However, MAE genes in control 
and ASD showed some enrichment with common variants from GWAS data of BPD and 
SCZ (Supplementary Fig. 6d).
Allele shift regions enriched in minor allele MAE in ASD and dup15q and snoRNAs
We have so far demonstrated that ASD and dup15q are associated with an increased rate of 
genes showing minor allele MAE that are enriched on chromosomes 14 and 15 and overlap 
known ASD risk genes, especially those harboring deleterious mutations that act via 
haploinsufficiency. Interestingly, the genomic regions showing MAE allele shifts from major 
to minor allele in both ASD and dup15q relative to controls are located on just a few 
chromosomes (Table 1a and 1b) and overlap regions known to harbor ASD-associated 
CNVs37. Among commonly existing MAE alleles, the frequencies of the allele shift in ASD 
and dup15q are 15.52% and 2.62%, respectively. To understand the effect of this apparent 
MAE allele shift in ASD, we compiled a set of high confidence genomic regions which we 
called “allele shift rich regions”. We defined these regions as having such allele shifts in 
both ASD and dup15q relative to controls. This analysis identities only two genomic 
regions, 14q32 (chr14:101302,638–101,544,745) and 15q11 (chr15:25,223,730–
25,582,395), which are known imprinted loci that have many small splice junctions (Fig. 6) 
and show continuous high expression (Supplementary Fig. 7) as single transcript units38–40. 
Both regions also contain tandem repeats of multiple orphan C/D box snoRNA genes39,40, 
which are located within repeated introns of MEG840, SNURP-SNFPN, and SNHG14 
transcripts. Indeed, all known orphan C/D box snoRNA genes are located within these two 
regions, including SNORD113 and SNORD114 at 14q32 (Fig. 6a), and SNORD64, 
SNORD107, SNORD108, SNORD109, SNORD115, and SNORD116 at 15q11 (Fig. 6b). 
These snoRNA genes are highly expressed in the brain39,40 and control alternative splicing 
of specific target genes without complementarity to rRNA within their sequences39–41.
To begin to understand the impact of the allele shift at the regions, we next assessed whether 
they were differentially expressed in ASD or dup15q cases versus controls. Analysis of 
RNA-seq data showed regional downregulation of 15q11 in ASD (p-value=0.0016; Fig. 7a). 
SNORD116–24 downregulation was observed in ASD and dup15q from small non-coding 
RNA-seq data (sncRNA-seq) data42 (p-values=0.0347 and 0.0019, respectively; Fig. 7b). As 
snoRNA genes regulate the splicing of downstream targets, allele shifts would change 
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potential binding and may alter the splicing patterns of snoRNA targets. To test this 
hypothesis, we used a known splicing target list41 of the snoRNAs to investigate whether 
these genes show splicing changes based on RNA-seq data from postmortem ASD brain4. 
The accuracy of these splicing target predictions has been confirmed in previously published 
studies43,44 providing experimentally validated snoRNA targets including some studies in 
neuronal cells43. From receiver operating characteristic analysis44, the splicing target 
prediction showed a 90–100% true positive rate within a 0.02–0.3% false positive rate range. 
Indeed, we find that the snoRNA target genes show more splicing changes in ASD and 
dup15q compared with controls (Fisher’s exact tests: OR=1.40 and 1.72, respectively; Fig. 
7c). The snoRNA targeting sites were located significantly proximal to alternatively spliced 
junctions of their target genes in ASD (Supplementary Fig. 8a), and their splicing changes 
show significant correlations with the expression changes of their specific snoRNAs 
(Supplementary Fig. 8b and 8c). When one snoRNA has two different targets, their splicing 
changes also show strong correlation (Supplementary Fig. 8d).
Furthermore, among snoRNA targets, genes showing altered splicing changes in ASD and 
dup15q are significantly enriched for known ASD risk genes (SFARI) and genes encoding 
PSD proteins compared with the other target genes without splicing changes (Fig. 7d; 
Methods). These results are consistent with the bioinformatic predictions above and 
potentially implicate disruption of snoRNA-mediated splicing of synaptic ASD risk genes in 
the pathophysiology of ASD. Moreover, the shared patterns of MAE allele shifting in ASD 
and dup15q provide a potential convergent biological mechanism linking idiopathic ASD 
and dup15q syndrome. Like ASE genes (Fig. 2c), the splicing changing snoRNA targets in 
ASD and dup15q showed significant enrichment with two different datasets of de novo ASD 
risk variants (in ASD, OR=2.30 (p-value=0.04) for the first and OR=7.42 (p-value=0.005) 
for the second; in dup15q, OR=2.14 (p-value=0.05) for the first and OR=5.97 (p-
value=0.02) for the second; Fig. 7e).
Discussion
This study provides the first large-scale, genome-wide investigation of ASE patterns in 
human brain samples from subjects with ASD and dup15q. We identify different patterns of 
ASE in ASD than in controls including overall fewer sites showing ASE in ASD. However, 
when ASE does occur, ASD subjects show a preferential minor allele predominance, rather 
than the usual pattern of major allele predominance particularly in instances of pure 
monoallelic expression. Genes exhibiting ASE were also enriched in genes that harbor de 
novo ASD risk variation, consistent with the expectation that such genes could be highly 
dosage sensitive. It follows from this that ASE could increase ASD risk from the de novo 
mutations in highly dosage sensitive genes. Moreover, since snoRNA target genes showing 
splicing changes are enriched in genes showing ASE and de novo ASD risk variation, 
snoRNA mediated splicing changes could enhance ASD risk in dosage sensitive genes that 
harbor de novo risk variants. In ASD, loci showing minor allele MAE were enriched for 
known ASD-risk genes and the post-synaptic density genes. Furthermore, we identified two 
orphan C/D box snoRNA rich regions at 14q32 and 15q11 strongly enriched for ASD-
related MAE change. These loci were also enriched for minor allele MAE in dup15q 
demonstrating convergence between known genetic risk factors and DNA methylation 
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changes in brain. The allele shift towards minor allele MAE in ASD highlights the 
importance of understudied mode of gene regulation in ASD pathogenesis, and the snoRNA-
mediated splicing changes point to novel potential biological disease mechanisms in brain.
Our results were enabled by an optimized pipeline that we developed to perform a large-
scale genome-wide ASE investigation in ASD overcoming multiple potential challenges. To 
maximize transcriptome-wide SNP collection, we combined results from multiple methods 
including SNP array, imputation, and RNA-seq based genotyping. This is especially 
important for identifying SNPs with MAE, which often are missed by RNA-seq based 
genotyping. We generated a masked reference genome to filter out all potential reference 
biased SNPs during mapping to increase the accuracy of ASE measurement and to reduce 
false positive results. We further filtered SNPs showing association with ethnicity to identify 
generalizable ASE patterns across populations. We used the largest number of human 
postmortem brain samples from subjects with ASD4 including multiple brain regions per 
individual to bolster reproducibility of results. Finally, we employed a novel linear mixed-
model approach that accounts for sample-level variation in order to quantify ASE patterns 
across ASD and control groups. This optimized work-flow can guide future large-scale 
genome-wide ASE studies in disease.
Preferential major allele expression is the most common pattern observed in most cases of 
MAE presumably because it can provide a buffer against unexpected, potentially deleterious 
rare SNP risks that might increase risk for disease12. Consistent with this interpretation, rare 
SNPs show more preferential major allele expression than common SNPs. Common SNPs, 
in general, show more balanced expression patterns as expected for non-deleterious alleles 
that have been through the filter of natural selection. Since rare alleles are more likely to be 
deleterious than common alleles45, the decrease in preferential major allele expression in 
ASD and dup15q, which could protect against the effect of deleterious rare alleles, could 
contribute to the risk of developing ASD. This is supported by the overlap of genes showing 
this pattern in ASD postmortem brain with genes harboring known ASD risk alleles.
We found a notable convergence between idiopathic ASD and dup15q, both of which show 
enrichment of allele shift from major allele MAE to minor allele MAE at specific loci on 
chromosomes 14 and 15. 15q11-q13 duplication causes hypermethylation at 15q11-q1319 as 
well as a genome-wide increase of minor allele MAE. Both idiopathic ASD and dup15q 
have increased minor allele MAE compared to control and the same trends of regional and 
snoRNA expression changes at the two regions showing a high frequency of shifts from the 
major to minor alleles. Idiopathic ASD shows extensive allele shifting at the 15q11 locus, 
which suggests that strong allele-specific methylation may be regulating gene expression46 
in a similar fashion as the 15q11-q13 duplication itself. Because idiopathic ASD and dup15q 
share similar expression patterns within both of the allele shift rich regions, the splicing 
changes targeted by snoRNA may be strongly related to disease pathogenesis.
An allele shift rich region was identified at 14q32 which also contains two dense clusters of 
over 50 miRNAs within the delta-like 1 homolog-type 3 iodothyronine deiodinase (DLK1-
DIO3) domain locus38. These clusters are maternally expressed (Fig. 6) and share an 
upstream imprinting control region with the other genes at the allele shift rich region38. 
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Several of these miRNAs have been shown to be down-regulated in cancer47 and 
schizophrenia38, and their targets are enriched in axon guidance pathways. This could 
represent a point of convergence between ASD and schizophrenia, which are known to have 
significant phenotypic and genetic overlap38.
These analyses highlight preferential minor allele expression and orphan C/D box snoRNA 
mediated splicing changes as two novel forms of genetic regulation altered in ASD. Our 
novel ASE identification approach incorporates both allele frequencies and quantitative 
measures of allelic imbalance. We identified strong enrichment of minor allele containing 
transcripts in ASD, which were further enriched for known ASD risk genes, including PSD 
components32, RBFOX1 targets30, HuR targets29, and FMRP targets28. However, we 
recognize that the studies of PSD components, and FMRP and RBFOX1 targets rely on 
postnatal data. Prenatal studies could identify other pathways, including chromatin 
modifiers. However, we note that even using these postnatal data, we did identify overlap 
with de novo mutation containing ASD risk genes, which include chromatin modifiers and 
transcriptional regulators. Furthermore, we identify evidence supporting orphan C/D box 
snoRNA mediated splicing changes in ASD brain providing the first evidence of an 
association between snoRNA and ASD.
Among all forms of small non-coding RNAs (sncRNAs), miRNA have received the most 
focus as a target for ASD and other psychiatric diseases studies38,42. Although the orphan 
C/D box snoRNA is a small family of snoRNAs existing only at chromosomes 14q32 and 
15q11, this family controls the splicing of a unique set of about 400 target genes that are 
distributed across genome. Although we could not find enrichment for common ASD risk in 
these targets, it may be due to simple lack of power of current GWAS studies in ASD. The 
most recent ASD GWAS contained over 45,000 subjects35 and yet identified an order of 
magnitude lower significant loci than a similar size study of schizophrenia48, consistent with 
substantially less power in ASD. Once larger more conclusive GWAS results are available, 
future studies can identify whether this group of genes is enriched in common variation that 
could contribute to polygenic risk for ASD. The allele shift rich regions in both idiopathic 
ASD and dup15q are directly overlapping with these orphan C/D box snoRNA repeat loci. 
Remarkably, we identified splicing changes in the downstream targets of these snoRNA 
genes providing a potential mechanistic link between genetic, epigenetic, and transcriptomic 
changes in ASD. These results highlight novel genetic and epigenetic regulations in ASD 
identifying novel biological mechanisms warranting further investigation.
Methods
Samples, RNA-seq, and genotyping.
As in our previous study4, human postmortem brain samples were acquired from the Autism 
Tissue Program at the Harvard Brain Bank, the University of Maryland Brain and Tissue 
Bank (a Brain and Tissue Repository of the NIH NeuroBioBank), the UK Brain Bank for 
Autism and Related Developmental Research, and the MRC London Neurodegenerative 
Diseases Brain Bank. A total of 263 brain samples were collected from BA9, BA41, and 
vermis of 40 controls and 56 ASD cases including 8 cases with dup15q syndrome. Though 
most sample information was already published4, we provided it again including further 
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information (Supplementary Table 1). After RNA-seq library preparation with ribosomal 
RNA depletion (Illumina TruSeq v2 with Ribozero Gold (Illumina)), RNA-seq was 
performed using Illumina HiSeq2000 to generate 50bp paired-end reads as published4. 
Sample genotyping was performed using Illumina Omni2.5 SNP array.
Preparing masked reference and RNA-seq data mapping.
To avoid reference bias, we first prepared a masked reference genome after collecting all 
possible SNPs. We compiled the set of SNPs (39,683,000 SNPs) from multiple sources 
including those present on SNP arrays (Omni2.5 SNP: 2,372,783 SNPs; Affymetrix: 
905,721 SNPs), those present in 1000 Genomes (38,270,182 SNPs)26,27, and those identified 
in the brain samples from RNA-seq based SNP calling (3,163,431 SNPs).
RNA-seq based SNP calling was performed using: GATK50 and Samtools51. To increase 
their SNP calling accuracy, we optimized bam files following the recommended GATK 
pipeline50 (Supplementary Fig. 1a). After updating mapping quality scores, we added group 
headers and read groups. Once reordering chromosomes and marking duplicate reads, we 
recalibrated quality scores. Possible false positive SNP calling data was filtered out based on 
the common outputs of GATK and Samtools. We removed indels and retain only single base 
variants (e.g., SNPs). When multiple SNPs were present at the same genomic coordinate, we 
randomly kept only one for downstream analysis. Using these collected SNPs, we masked 
the hg19 reference sequence with randomly selected third alleles to minimize systematic 
mapping bias. We mapped all RNA-seq data to this masked reference genome using 
TopHat252 with Ensembl v73 annotations and the following parameters:
tophat ‐g 10 ‐p 8 ‐r 99 ‐‐no‐novel‐juncs ‐G
Filtering out reference biased SNPs.
For further prevention of potential reference mapping bias by TopHat2, we generated a 
simulated RNA-seq dataset consisting of all possible 50bp reads overlapping each SNP for 
both reference and alternative alleles (100 reads total per SNP). We mapped these simulated 
reads to the masked reference genome as described above. We identified any SNPs that show 
reference bias (despite mapping to the masked reference genome) using chi-square test (p-
value≦0.05 and read depth<10). These reference biased SNPs were removed from 
downstream analysis.
Genotyping.
SNP array data were imputed to 1000 genomes using Mach/Minimac53,54. Imputed SNPs 
were filtered out by their output quality (filtered out based on R2 and score values: R2<0.5 
and score value>score digit ± 0.2) and Hardy-Weinberg equilibrium (HWE; p-
value<1.0X10−6) to yield 10,992,184 high quality imputed SNPs.
To generate additional genotyping coverage, we did RNA-seq based genotyping using the 
following parameters:
Homozygous SNP: a1 ≧4, a1 > 10 × a2, and a3 < 0.5 × a1
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Homozygous SNP: a2 ≧ 2, a1 ≦ 10 × a2, and a3 < 0.5 × a2
We called the SNPs based on the first-, second-, and third-most abundant allele counts (a1, 
a2, and a3) in mapping transcript, respectively. We filtered out the genotyped SNPs if they 
did not pass the HWE filter (p-value<1.0X10−6). Compared with the previously published 
RNA-seq based genotyping methods by Quinn et al.55, these genotyping parameters show 
much higher accuracy with sensitivity exceeding 95% (Supplementary Fig. 1b) and 
specificity in the range of 90–95% (Supplementary Fig. 1c; see Quinn at el.55 for accuracy 
tests).
We integrated the three genotyping data, SNP array, imputation, and RNA-seq based 
genotyping. If we observed discordance among these methods, we weighted the data in the 
following order, favoring SNP array > imputation > RNA-seq based genotyping.
Ancestry Identification.
Using the integrated genotyping data, we identified ancestry by a multidimensional scaling 
(MDS) plot with HapMap3 populations. We categorized our samples into European, 
Mexican, Asian, African, and ambiguous groups (Supplementary Fig. 1d).
Group based ASE identification.
We first studied ASE patterns within each tissue group (BA9, BA41, vermis, and cortex 
(BA9 and BA41)) considering idiopathic ASD and control. In this study, we excluded 
dup15q samples from the other ASD case since they had clear structural chromosome 
alteration that causes ASD. We called the other ASD cases as idiopathic ASD for which the 
causes are unknown. Control brain samples were from someone who were not diagnosed as 
ASD and whose structural chromosome alternations were unknown.
First, we collected SNPs if “good” SNPs were present in 80% of samples15. SNPs were 
defined as “good” SNPs if they had the 3rd and 4th allele counts less than 5% of the major 
allele. We also collected SNPs considered “present” in at least 20% of samples15. “Present” 
is defined as the percent of individuals that have more than 10 allele counts. “Good” and 
“present” filters account for expression levels and RNA-seq read mapping error, 
respectively.
For each heterozygous SNP, we counted the number of reads mapping to each allele. To 
normalize for differences in library size, results were converted to “reads per kilobase of 
SNP area length per million mapped reads” (RPSM) values defined as:
RPSM = allele mapped read # + 1total uniquely mapped read #
1, 000, 000 ×
SNP area length bp
1, 000
The SNP area length is calculated as (read length X 2) - 1, and mapped reads can reach a 
SNP within the SNP area.
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For each group, ASE was quantified at SNP level using a linear mixed model (log2(RPSM) 
~ allele + age + sex + sequencing batch + RNA integrity number (RIN) + brain bank + 
ancestry, rand = ~1|biolrep/subject). Fixed effects included allele, age, sex, sequencing 
batch, RIN, brain bank, and ancestry. Biological replicate (biolrep) and subject were 
included as random effects. Biological replicate is RNA-seq data replicates. To ensure if 
groups were balanced with respect to these covariates, we removed samples based on age 
(≦7), brain banks (The UK Brain Bank for Autism and Related Developmental Research and 
the MRC London Neurodegenerative Diseases Brain Banks), and SNP annotation 
(mysterious) (Supplementary Table 1)4. We removed the other possible covariates (PMI, 
brain mass, and GC contents) that did not affect this ASE study. GC content was tested using 
AT and GC dropout values from Picard (https://broadinstitute.github.io/picard/; 
Supplementary Table 1). The AT and GC dropout values are the percentage of misaligned 
reads at low GC (GC<50%) or high GC (GC>50%) conditions, respectively. In BA9 
samples, the distributions of the covariate values were balanced between control and ASD 
(Supplementary Fig. 1e). When we identified ASEs from additional linear mixed model 
including the covariates, the covariates did not show significant p-values without affecting 
the ASE results.
We investigated both autosome and chromosome X. For no PARs on chromosome X, we 
considered only female data. PARs were defined as: PAR1(chrX:60,001–2,699,520, chrY:
10,001–2,649,520), PAR2 (chrX:154,931,044–155,260,560, chrY:59,034,050–59,363,566), 
and PAR3 (chrX:88,400,000–92,000,000, chrY:3,440,000–5,750,000)56.
Based on the p-values of the ancestry covariate from the linear mixed model regression, we 
filtered out SNPs showing ethnicity biased allele expression. After LD based SNP pruning 
using PLINK (R2 cutoff=0.2)57, we counted the number of LD-independent SNPs and 
identified ASE SNPs by Bonferroni correction.
To filter out potential indel-inducing reference bias from the identified ASEs, we considered 
1,450,137 imputed indels identified during the above genotyping step. Among them, we 
selected only accurate 1,040,318 indel outputs from Mach/Minimac (deletions (≦3 bp) and 
inserts (1 bp)). We further filtered them out by the imputation quality (R2<0.5 and score 
value>score digit ± 0.2), HWE (p-value<1.0X10−6), missing genotype ratio (<0.05), and 
MAF (<0.01) to yield high quality imputed indels. To test indel-inducing reference bias, we 
selected 457,817 indels that show heterozygous types at least one sample.
Based on the masked reference genome, we generated a simulated RNA-seq dataset (50mer 
fastq file), which overlaps each indel area. It contains both indel containing and not 
containing sequences. We aligned the fastq file to the masked reference genome using 
TopHat2 and identified possible indel-inducing reference biases (chi-square test p-
value≦0.05) from their proximal SNPs (read depth≧10). Once SNPs show the reference 
biases from at least one sample that has heterozygote genotypes from both indels and SNPs, 
we filtered them out from the ASE results. To genotype SNPs, we integrated SNP array, 
imputation, and RNA-seq based genotyping as described above.
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To compare ASE across groups, Manhattan plots were generated with the p-values of the 
allele covariate from the linear mixed model regression using the qqman R package (https://
cran.r-project.org/web/packages/qqman/; Fig. 3b). If ASE SNPs were located in gene 
bodies, we called the genes as ASE genes. The ASE genes were compared using area-
proportional Venn diagrams58 (Fig. 3c).
Individual based ASE identification.
We next studied ASE within individual samples comparing differences in allele counts for 
heterozygous SNPs. We used only “good” SNPs in at least 80% of samples (as defined 
above) without considering the present filter. P-values for each SNP were calculated using 
Fisher’s exact test. After LD-based SNP pruning, ASE SNPs were identified by Bonferroni 
correction (as described above). We filtered out indel-inducing reference biased SNPs as 
described above.
For each cortical sample, ASE rates were calculated per chromosome as the number of ASE 
SNPs / total number of tested SNPs. Differences in the ASE rate was tested using Wilcoxon 
rank sum test (Fig. 3d).
Evaluation of identified ASE.
To test ASE identification accuracy, we identified haplotype blocks using PLINK with the 
SNPs showing no ethnicity biased allele expression. We calculated deviations of log2(fold 
change) values (the beta values of allele covariate from the group based ASE identifications) 
per haplotype block in cortex and compared their distributions with normal distributions 
(Supplementary Fig. 1f and 1g). For further validation, we compared ASE genes identified 
in our study with those present in dbMAE (https://mae.hms.harvard.edu/)22 using Fisher’s 
exact test (Supplementary Fig. 2a). Of note, dbMAE mostly includes non-neural tissues, and 
we considered its human and mouse data. Nevertheless, we observe strong overlap between 
them providing validation of our ASE genes. For additional external validation, we 
generated data as following GTEx data analysis24. Like the method of GTEx data, we 
considered only heterozygote SNPs and followed the same p-value cutoff of GTEx data. We 
considered the ASE SNPs once their p-values are below 0.005 at the previous individual 
based ASE identification. Like GTEx data, we calculated ASE rates per tissue 
(Supplementary Fig. 2c). To compare the GTEx data24 with our data, we compared the mean 
of ASE rates from the tissues.
ASE and expression comparison.
We calculated less expressed allele expression fraction per each heterozygote SNP from a 
sample, UMB5303 (tissue: BA41). The fraction is a2 / (a1 + a2). a1 is more expressed allele 
read count, and a2 is less expressed allele read count. If the SNP has more than 10 mapped 
reads, we calculated log2(RPSM). Based on the less expressed allele expression fraction, we 
grouped the SNPs as imbalance and other groups. The fractions of the imbalance group were 
equal or less than 30%. The fractions of the other group were greater than 30%. We 
compared their log2(RPSM) values using KS tests (Supplementary Fig. 2d).
Lee et al. Page 14
Nat Neurosci. Author manuscript; available in PMC 2020 February 26.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Gene set enrichment.
Gene set enrichment analyses were performed using logistic regression accounting for gene 
length as a covariate. Heatmaps were prepared as showing OR and FDR corrected p-values 
for enrichment, if significant. For known ASD risk gene list (SFARI gene), we selected 
genes from category 1, 2, and 3 corresponding to gene scoring criteria (https://gene.sfari.org/
autdb/GS_Home.do); Supplementary Table 6) The gene list was previously used at the 
previous publication36.
For this gene set enrichment studies, we also used known imprinted genes 
(www.geneimprint.com), PSD32, FMRP target28, HuR target29, and RBFOX1 target 
genes30, cell marker genes31 (neuron, astrocyte, oligodendrocyte, microglia, and 
endothelial), expression up- and down-regulated genes in ASD cortex4 (Supplementary 
Table 6). HuR target gene list29 was collected from photoactivatable ribonucleoside 
crosslinking and immunoprecipitation (PAR-CLIP) data instead of RNA binding proteins 
immunoprecipitation complementary DNA array (RIP-chip) data41 since PAR-CLIP data 
identified RNA binding proteins binding sites more precisely than RIP-chip (Supplementary 
Table 6).
For the de novo variant data, we used the risk genes containing rare de novo likely gene 
disrupting mutations in SCZ, ID, and ASD from the dataset of Iossifov et al.45 
(Supplementary Table 6). Since this list is not based on the most stringent statistical 
thresholding (353 genes for ASD), we used additional risk gene lists from other work to 
cross reference. This includes Sanders et al.33 who identified risk genes after integrating 
small de novo deletions using the transmission and de novo association model. For the risk 
gene list, we analyzed gene set enrichment with different FDR cutoffs (FDR≦0.01, 
0.01<FDR≦0.05, and 0.05<FDR≦0.1) and found the highest enrichments using the most 
stringent FDR cutoff. of FDR≦0.01, which we report in our study (Supplementary Table 6).
For gene set enrichment study with risk variants from psychiatric diseases, we considered 
GWAS data from Psychiatry Genomics Consortium34,35 and de novo variant data32,33. For 
the GWAS data, we considered five psychiatric diseases, ADHD, BPD, MDD, SCZ, and 
ASD. Gene set enrichment analyses were performed by MAGMA version 1.07b59. For the 
analyses, annotation steps were performed first using hg18 for the dataset of Cross-Disorder 
Group of the Psychiatric Genomics34 and hg19 for the dataset of Grove et al.35. Genes 
boundaries were set stringently between transcription start and stop sites. In the next gene 
analysis steps, LD was calculated using the 1000 Genome European ancestry reference 
dataset. Gene set analyses were then performed to create aggregate statistics for each gene as 
considering the LDs.
Gene ontology (GO) analyses were performed using GOrilla60,61 and visualized through 
REViGO49. For both studies, brain expressed genes were used as background genes that 
have more than 10 allele counts (Supplementary Table 6).
Quantitative allele imbalance study in idiopathic ASD.
From SNPs genotyped by SNP array or imputation, we collected SNPs based on meeting the 
criteria of at least 20% present and 80% good15. These criteria included rare SNPs. If SNPs 
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showed the reference biases from at least one sample that has heterozygote genotypes from 
both proximal indels and SNPs, we filtered them out as described above. We calculated 
minor allele expression fractions (minor allele expression / total expression) and less 
expressed allele expression fractions. We visualized their distributions using ggplot2 R 
package (http://ggplot2.org/) and compared them between control and idiopathic ASD at 
autosome (Fig. 4a and Supplementary Fig. 4b) and chromosome X (Supplementary Fig. 4c). 
Although there are three different PARs at chromosome X, we combined their data into one 
dataset due to their small SNP numbers. At no PARs, we used only female data so that we 
considered two alleles from chromosome X.
To compare the number of SNPs that can introduce LoF mutation, amino acid change, and 
synonymous mutation (Fig. 4d), we counted SNPs for three different allele categories. They 
contain alleles showing balanced expression, major allele MAE, and minor allele MAE. For 
LoF mutation, we counted alleles located at stop codon generating mutations, 5’ splice site 
mutations, or 3’ splice site mutations.
MAE study.
For the genome-wide views of MAE SNPs, we used the previously described qqman R 
package. For major and minor allele MAE SNPs, we visualized them on the different lines 
(Supplementary Fig. 5). To visualize allele shift to minor allele MAE at UCSC genome 
viewer, we prepared wig files as assigning constant value (1) for each allele shift (Fig. 6). To 
visualize splice junctions at UCSC genome browser, we combined all bed files from 
TopHat2 outputs and prepared a juncs file using bed_to_juncs program39.
sncRNA-seq data process.
Based on RNA sample availability, our previous study prepared 50mer single-end read 
sncRNA-seq data42. The data were generated by Illumina HiSeq2000 from rRNA depleted 
libraries. To remove adaptor sequences, the sncRNA-seq read are processed by fastx_clipper 
of FASTX-Toolkit (http://hannonlab.cshl.edu/fastx_toolkit/index.html) and mapped with 
bowtie262. From uniquely mapped reads, we counted read number for smaller than 100bp 
genes using htseq-count63 and calculated their reads per kilobase of transcript per million 
mapped reads (RPKM)64. We used a linear mixed model (expression ~ condition + age + sex 
+ sequencing batch + RIN + bank, rand = ~1|biological replicate/subject) to identify 
differentially expressed genes. Expression is log2(RPKM), and the expression could be 
driven by condition, age, sex, sequencing batch, RIN, and brain bank. Also, as the random 
factors we used biological replicate and subject. We removed samples based on age (≦7) and 
brain banks (The UK Brain Bank for Autism and Related Developmental Research and the 
MRC London Neurodegenerative Diseases Brain Banks).
For snoRNA gene expression change study in the allele shift regions, we calculated the 
log2(fold change) from the linear mixed model regression outputs. We considered 51 
snoRNAs that have PRKMs equal or greater than 1 (Fig. 7b).
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Regional expression and splice junction study.
To study regional expression change at the allele shift rich regions, we calculated their 
log2(RPGMs) values65 from uniquely mapped reads of RNA-seq data and compared them 
between control and cases (Fig. 7a).
snoRNA target splicing change study.
For orphan C/D Box snoRNAs at the allele shift rich regions, we relied on previously 
identified splicing targets41. We identified splicing changing genes that show ≧2SD 
alternative splicing change (beta values from the previously published linear mixed model 
regression data4) in ASD and dup15q versus controls. Using a Fisher’s exact test, we 
assessed if the snoRNA target genes show more alternative splicing changes in ASD and 
dup15q versus other non-snoRNA targets (Fig. 7c). Among the snoRNA target genes, we 
performed a gene set enrichment study for gene showing significant splicing changes (Fig. 
7d).
Summary of statistical methods.
Sample sizes.—No statistical methods were used to pre-determine sample sizes but our 
sample sizes are larger than to those reported in previous publications that studied ASE8,15.
Normality of data distribution.—For ASE identification and quantitative allele 
imbalance study, normality was not formally tested, but data distribution was assumed to be 
normal but this was not formally tested.
Randomization.—To avoid reference bias, we randomized allele selection for a masked 
reference preparation.
Blinding.—Data analysis was not performed blind to the metadata information of the brain 
samples.
Code availability.
The R code for the ASE identification using a linear mixed model is provided in 
Supplementary Software 1.
Data availability.
The detailed description of brain samples is provided in Supplementary Table 1. For each 
tissue, group-based ASE identification results are available in Supplementary Tables 2 and 3. 
We also include gene lists that we used for gene set enrichment and GO analysis that 
includes brain expressed gene that we used for our study (Supplementary Table 6). Raw next 
generation sequencing data from human postmortem brain samples are available from 
published RNA-seq4 and sncRNA-seq42 studies. They have been deposited to the 
PsychENCODE Knowledge Portal (http://dx.doi.org/10.7303/syn4587609).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
A schematic of the pipeline for analysis of ASE. RNA-seq data were generated from 263 
brain samples across three brain regions from subjects with 56 ASDs and 40 controls. After 
preparing a masked reference file, RNA-seq data were mapped, and reference biased SNPs 
were removed (Methods). Genotyping data from SNP array, imputation, and RNA-seq based 
genotyping were used for ancestry identification and heterozygous SNP identification for 
ASE investigation. Group based ASE was investigated across case and control groups using 
a linear mixed model within each brain region separately. Individual based ASE analysis was 
performed within each individual sample using Fisher’s exact test. The results underwent 
LD pruning followed by multiple test correction (Bonferroni). As post hoc analysis, we 
filtered out reference biased SNPs generated by proximal indels.
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Figure 2. 
ASE patterns shared among cases and controls. (a) Venn diagram comparing the overlap of 
ASE genes from three brain tissues, BA9, BA41, and vermis. (b) Enrichment analyses of the 
ASE genes with ASD-relevant (SFARI gene list36; Methods) and cell-type specific gene lists 
(Methods)31. Across all three brain regions, ASE genes showed strong overlap with known 
imprinted genes (Methods) as well as targets of FMRP28, HuR29, and RBFOX130. Plot 
showed ORs and FDR corrected p-values for enrichment, if significant. (c) Gene set 
enrichment study of ASE genes with risk variants in psychiatric disease dataset. From de 
novo variant datasets45,33, we considered SCZ, intellectual disorder (ID), and ASD. The 
dataset for SCZ, ID, and ASD1 were gene lists containing de novo likely gene disrupting 
mutations from the previous study of Iossifov et al.45, and the data for ASD2 represents risk 
genes integrating de novo copy number variations (FDR≦0.01) from the study of Sanders et 
al.33 (Methods). The risk variants from GWAS34,35 were considered for ADHD, BPD, 
MDD, SCZ, and ASD (Methods). Here, ASD1 and ASD2 represent the GWAS datasets 
from the Cross-Disorder Group of the Psychiatric Genomics34 and Grove et al.35, 
respectively. If significant, the plot shows ORs and FDR corrected p-values for de novo 
variant datasets and FDR corrected p-values for GWAS. The sample numbers of BA9, 
BA41, and vermis are 67, 64, and 64, respectively.
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Figure 3. 
ASE patterns distinguish control and idiopathic ASD brain. (a) The comparison of ASE 
genes from BA9, BA41, and vermis within control and idiopathic ASD groups. (b) 
Manhattan plots for control and idiopathic ASD cortex show broad distribution of genomic-
loci exhibiting ASE. Sample numbers of control and idiopathic ASD brains are 69 and 62, 
respectively. (c) Venn diagram showing comparison of ASE genes across groups in cortex. 
(d) ASE rates for individual samples from ASD and control groups (Methods). Idiopathic 
ASD samples (n=32) show lower overall rates of ASE compared with controls (n=31). For 
the violin plots, ASE rates were calculated per chromosome form each cortical sample 
(Methods). The Wilcoxon rank sum test was two-sided. (e) GO analyses are shown for 
common ASE genes between control (n=69) and idiopathic ASD groups (n=62). At the 
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above interactive graph, the bubble color indicates the p-value of the GO term, and bubble 
size indicates its frequency49. The p-values and other results of the GO analysis are at 
Supplementary Table 4. Highly similar GO terms are linked by edges, and the line width 
indicates the degree of similarity. At the below figure, the white, yellow, and orange boxes 
represent p-value>10−3, 10−5<p-value≦10−3, and 10−7<p-value≦10−5, respectively.
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Figure 4. 
Quantitative allelic imbalance in idiopathic ASD and control cortex. (a) The distribution of 
minor allele expression fraction for idiopathic ASD (red) and control (blue) groups for 
autosomal SNPs. The majority of loci show balanced expression. The density plot near 0% 
and 100% are zoomed in to show patterns of monoallelic expression. (b) SNP fractions of 
balanced, imbalanced, or MAE expression per MAF. (c) SNP fractions showing preferential 
major or minor allele expression per MAF. At (b) and (c), open circles are for control, and 
close circles are for idiopathic ASD. (d) The comparison of SNP numbers, which possibly 
can cause LoF mutation, amino acid change, or synonymous mutation at control cortex. 
Major allele MAE has a role to prevent deleterious LoF and missense mutations. Y-axes 
show SNP numbers. (e) SNP counts showing preferential expression of the major and minor 
alleles in control and idiopathic ASD. Their ratio is expressed as the Minor/Major.
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Figure 5. 
MAE SNPs across control, ASD, and dup15q groups. (a) Venn diagram showing overlap of 
MAE SNPs across groups. Less than 15% of MAE SNPs were overlapped between cases 
and controls. (b) The number of major allele MAE SNPs and minor allele MAE SNPs across 
groups. Both chi-square test p-values in ASD and dup15q compared to control are <2.2e-16. 
(c) Minor allele MAE fraction (minor / (major + minor)) across chromosomes for control, 
ASD, and dup15q. (d) Gene set enrichment for major and minor allele MAE genes in control 
(n=69), ASD (n=62), and dup15q (n=15) groups (Methods). Enrichment was assessed for 
known ASD risk genes (SFARI36; Methods), known imprinted (Methods), PSD32, FMRP 
target28, HuR target29, and RBFOX1 target genes30. Enrichment was assessed separately for 
genes showing major allele and minor allele MAE. Dup is for dup15q.
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Figure 6. 
Allele shift rich regions at ASD and dup15q. (a) and (b) The allele shift rich regions on 
chromosome 14 (chr14:101,302,638–101,544,745; 242,108bp) (a) and on chromosome 15 
(chr15:25,223,730–25,582,395; 358,666bp) (b). Chromosomal locations of allele shifting to 
minor allele MAE are shown on top. Allele shift to minor allele MAE in ASD and dup15q 
tracks shows the allele shifts. We visualized all splice junctions identified from RNA-seq 
mapping data and their chromosomal directions, which are shown with + and −. The RefSeq 
Genes model is shown on the bottom, indicating known imprinted genes, maternally 
(outlined in red rectangles) and paternally (outlined in blue rectangles) expressed genes. Dup 
represent dup15q.
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Figure 7. 
The characterization of the allele shift rich regions in ASD and dup15q. (a) Regional 
expression changes of the common allele shift rich regions in ASD and dup15q. The X axes 
are log2(reads per kilobase of gene model per million mapped reads) (log2(RPGM)), and 
two tailed unpaired t-test p-values are 0.6397, 0.0016, 0.1538, and 0.1525 for 14q32 in ASD, 
15q11 in ASD, 14q32 in dup15q, and 15q11 in dup15q, respectively. Significantly down-
regulated regions are marked with an asterisk. 14q32 in ASD also has less mean than control 
like the others. The minimum, 1st quantile, median, 3rd quantile, and maximum values of 
the boxplots show at 14q32 (control: 1.671, 2.048, 2.270, 2.442, and 2.806; ASD: 0.7351, 
2.0643, 2.3355, 2.5048, and 2.9375; dup15q: 0.9286, 1.8464, 2.1859, 2.2984, and 3.0108, 
respectively) and 15q11 (control: 2.039, 2.890, 3.130, 3.302, and 3.524; ASD: 0.3255, 
2.5385, 2.8784, 3.2264, and 3.7170; dup15q: 1.114, 2.537, 3.105, 3.208, and 3.430, 
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respectively). (b) snoRNA gene expression changes in ASD and dup15q. Yellow and blue 
backgrounds indicated 14q32 and 15q11, respectively. Among snoRNA genes, 51 genes 
(RPKM≧1) are selected. From linear mixed model based differential expression gene study, 
significantly down-regulated SNORD116–24 genes (ASD: p-value=0.0347; dup15q: p-
value=0.0019) are marked with asterisks (*: p-value≦0.05; **: p-value≦0.001). (c) The 
number of snoRNA target genes and genes with splicing changes in ASD and dup15q. Two-
sided Fisher’s exact test p-values were shown at the bottom of tables. (d) Gene set 
enrichment analysis for snoRNA target genes. Among snoRNA target genes, we compared 
splicing change and the other genes in ASD and dup15q brain. The labels “mono major” and 
“mono minor” are major and minor allele MAE genes, respectively. The labels “expression 
up” and “expression down” represent significantly up- and down-regulated genes in 
idiopathic ASD4. (e) Gene set enrichment study of snoRNA target genes with risk variants in 
psychiatric diseases. For de novo variant datasets45,33, SCZ, ID, and ASD1 gene lists were 
de novo likely gene disrupting mutations45, and ASD2 represents ASD risk genes 
integrating de novo copy number variations (FDR≦0.01)33 (Methods). Plot showed ORs and 
the p-values if significant. The GWAS datasets were considered for ADHD34, BPD34, 
MDD34, SCZ34, and ASD34,35. Here, among ASD GWAS datasets, ASD1 and ASD2 
represent the Cross-Disorder Group of the Psychiatric Genomics34 and Grove et al.35, 
respectively. If significant, the plots show FDR corrected p-values for GWAS (Methods). 
Dup is dup15q patients. For (a), (b), (d), and (e), RNA-seq sample numbers of control, ASD, 
and dup15q are 69, 62, and 15, respectively.
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Table 1.
Allele shift regions to minor allele MAE in ASD (a) and dup15q (b) and previously reported relevant ASD 
related mutations. If there are more than two allele shifts, we defined its boundaries using their maximum and 
minimum coordinates.
a
Coordinate Region Size (bp) SNP # Previous ASD report
chr3:66,429,475 3p14.1 1 1 3p14.1 de novo microdeletion
chr14:101,325,640–101,390,093 14q32.2 64,454 2 14q32.2 duplication
chr15:23,889,739–25,561,958 15q11.2 1,672,220 83 15q11.2-q13.1 duplication
b
Coordinate Region Size (bp) SNP # Previous ASD report
chr2:207,173,390–207,175,070 2q33.3 1,681 2 2q33.3-q34 interstitial deletion,2q32.3-q37.3 duplication
chr11:2,690,293 11p15.5 1 1 11p15.5-p15.4 duplication
chr14:101,321,515–101,349,017 14q32.2 27,503 2 14q32.2 duplication
chr15:25,372,247 15q11.2 1 1 15q11.2-q13.1 duplication
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